Tradestie Institutional Equity Comparison Engine
RAPT vs ALMS โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
RAPT Overall Edge
RAPT Captures Institutional Edge (3โ0 Pillars ยท 6โ1 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to RAPT Therapeutics, Inc. Common Stock (RAPT) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, RAPT trades at N/M Forward P/E with 0.0% operating margin (-100.0% YoY revenue) versus ALMS at N/M Forward P/E and -5744.5% operating margin (-37.7% YoY). In options structure, RAPT sits in UNCLASSIFIED (<1st %ile IV; Dealer Gamma Walls on Pro) against ALMS sits in BREAKDOWN (8th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
RAPT N/M vs ALMS N/M Fwd P/E
Growth & Margin Winner
RAPT
Op Margin 0.0% vs -5744.5% ยท YoY -100.0% vs -37.7%
Momentum & Technical Winner
RAPT
1Y +480.2% vs -4.5% ยท 52W Pos 100% vs 2%
Options & Structure Winner
RAPT
UNCLASSIFIED (<1st %ile IV) vs BREAKDOWN (8th %ile IV)
RAPT
NASDAQ
RAPT Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$58.02
+0.07% 1D
Market Cap
$1.7B
1M Return
+0.68%
1Y Return
+480.2%
Forward P/E
N/M
Unified AI Score
52.4 / 100
HOLD
Tech 40.0
Fund 46.0
Flow 61.0
Mom 40.0
ALMS
NASDAQ
Alumis Inc. Common Stock
Pharmaceutical Preparations
$5.04
-9.91% 1D
Market Cap
$793.4M
1M Return
-17.57%
1Y Return
-4.45%
Forward P/E
N/M
Unified AI Score
43.3 / 100
HOLD
Tech 20.0
Fund 51.0
Flow 67.0
Mom 74.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
RAPT +480.2%
ALMS -4.45%
Spread: +336.46 pp (ALMS Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
RAPT TTM Op. Margin: 0.0%
ALMS TTM Op. Margin: -5744.5%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on RAPT vs ALMS. Trailing 12-month operating profitability (RAPT 0.0% vs ALMS -5744.5%) and valuation multiples (RAPT N/M vs ALMS N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | RAPT | ALMS | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $1.7B | $793.4M | Larger Scale | RAPT |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | -100.0% | -37.7% | Higher Growth | ALMS |
| Operating Margin (TTM) Profitability | 0.0% | -5744.5% | Higher Margin | RAPT |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -85.4% | -93.7% | Higher ROE | RAPT |
| 52-Week Range Position Momentum | 100% ($1โ$58) | 2% ($5โ$31) | Stronger Trend | RAPT |
| Beta / 30D Volatility Risk Regime | -0.02ฮฒ ยท 2% Vol | 2.23ฮฒ ยท 85% Vol | Lower Realized Risk | RAPT |
| Unified Institutional Score Composite Signal | 52.4 / 100 (HOLD) | 43.3 / 100 (HOLD) | Higher Composite | RAPT |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full RAPT vs ALMS Buy Guide
RAPT
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
<1st %ile
IV Regime
Compressed (<25th %ile)
ALMS
BREAKDOWN
91d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
8th %ile
IV Regime
Compressed (<25th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither RAPT nor ALMS registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.